Exact Sciences insider sale: 1,500 shares sold at $60 under 10b5-1 plan
Rhea-AI Filing Summary
Insider transaction summary: An officer of Exact Sciences Corporation sold 1,500 shares of common stock on 10/09/2025 at a price of $60 per share, leaving beneficial ownership of 14,085 shares reported on this form. The sale was executed under a written Rule 10b5-1 trading plan entered into on 03/03/2025, which the filer checked as applicable. In addition to the reported shares, the reporting person holds an aggregate 37,434 vested and unvested equity awards (options and restricted stock units), each restricted stock unit representing a contingent right to one share. The Form 4 was signed by an attorney-in-fact on 10/10/2025.
Positive
- Transaction executed under a Rule 10b5-1 plan dated 03/03/2025, providing regulatory clarity
- Officer retains substantial equity exposure: 14,085 shares plus 37,434 options and RSUs
Negative
- Officer sold 1,500 shares, reducing direct reported holdings to 14,085 shares
- Potential short-term selling pressure if additional awards vest or are exercised and then sold
Insights
Sale follows a pre-established Rule 10b5-1 plan; transparency improved.
The sale of 1,500 shares at $60 appears to have been executed under a Rule 10b5-1 trading plan dated 03/03/2025, which provides an affirmative defense against claims of trading on material nonpublic information when the plan meets regulatory conditions. Reporting the plan on the Form 4 increases disclosure clarity about the timing and intent of the transaction.
Dependence and risks include strict adherence to the plan terms and potential market perception of insider selling; monitor subsequent Form 4 filings and the remaining 37,434 equity awards for near-term vesting or additional sales that could further change insider ownership.
Officer retains meaningful equity exposure via shares and awards.
After the reported sale the officer beneficially owns 14,085 shares plus an aggregate 37,434 vested and unvested options/RSUs, indicating continued alignment with shareholder interests through ongoing equity exposure. Restricted stock units are described as contingent rights to receive one share each.
Key items to watch include the vesting schedule and exerciseability of the 37,434 awards and any future exercises or disposals that would affect dilution and the officer's realized ownership over the next 12 months.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 1,500 | $60.00 | $90K |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The transaction reported in this field was effected pursuant to a Rule 10b5-1 trading plan entered into on March 3, 2025. In addition to the shares of Common Stock reported on this Form 4, which total 15,641 shares, Mr. Herriott also holds, in the aggregate, an additional 37,434 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock.
